BMS-496

• Description:

  BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) [1].

• UNSPSC:

  12352005

• Target:

  DGK

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-496.html

• Purity:

  99.72

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CN(C1=CC=C(Br)N=C1C(N2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)=C5[N+]([O-])=O)C5=O

• Molecular Formula:

  C26H22BrF2N5O3

• Molecular Weight:

  570.39

• References & Citations:

  [1]Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15 (719) :eadh1892.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2407854-31-1]